Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HPV OncoPredict

Financiado

Cerrado

A Groundbreaking Stand Alone Diagnostic Kit to Predict Human Papilloma Virus Inf...

A Groundbreaking Stand Alone Diagnostic Kit to Predict Human Papilloma Virus Infections Evolving into Cervical Cancer Cervical cancer (CC) kills a 250,000 people annually, frequently affecting young women, and requires persistent infection with high-risk Human Papillomavirus (hrHPV) for its development. It is preventable, by HPV vaccination and t... ver más

30/04/2022

GeneFirst Ltd.

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

GENEFIRST LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-04-30

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 99% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

GeneFirst Ltd.

1.67M€ | Lider

HIANTIS

1.25M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

HoloCyt A rapid low cost cervical cancer screening platform 71K€ Cerrado

CHILI A Community based HPV screening implementation in Low Income... 3M€ Cerrado

VALID-SCREEN Validation of PreCursor M for enhanced Cervical Pre Cancer... 3M€ Cerrado

SixthSense Early diagnosis of cervical cancer through the validation of... 71K€ Cerrado

PIPAVIR Detection of persistent infections by human papillomaviruses 5M€ Cerrado

RTC-2015-3762-1 NUEVO DIAGNÓSTICO RÁPIDO Y DE ALTA SENSIBILIDAD PARA EL VIRU... 170K€ Cerrado

Duración del proyecto: 44 meses Fecha Inicio: 2018-08-22
Fecha Fin: 2022-04-30

Líder del proyecto

GENEFIRST LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cervical cancer (CC) kills a 250,000 people annually, frequently affecting young women, and requires persistent infection with high-risk Human Papillomavirus (hrHPV) for its development. It is preventable, by HPV vaccination and the implementation of population screening programmes, and it is curable if detected and treated early. Despite overwhelming evidence that detection of viral nucleic acids (HPV testing) in cervical cellular samples allows earlier detection of CC as compared to cytology (Pap smear), it is feared that its use as a stand-alone test in CC screening would be responsible for over-diagnosis and over-treatment. HPV OncoPredict is an innovative diagnostic device (IVD) capable of detecting all oncogenic hrHPV genotypes frequently causing cervical infection as well as allowing to accurate identification those 10% of infected women who are truly at risk of developing cervical cancer. With the use of novel viral biomarkers, HPV OncoPredict, starting from a single self- or clinician-collected cellular sample, will enable women to undergo both primary cervical screening and, if HPV-positive, subsequent triage. HPV OncoPredict will allow HPV testing to reliably replace Pap smears in cervical cancer prevention, as recently recommended by European guidelines, being based on a disruptive technology ahead of any competitor’s product and supported by key opinion leaders. The HPV testing market is huge (€315 M) with around 100 million tests performed each year. The consortium formed by GeneFirst and Hiantis, both highly innovative companies with patented technologies, has the capacity to bring HPV OncoPredict to success. HPV OncoPredict will not only shape the manner in which we stratify women at risk of developing cervical cancer, but also provide an accurate and cost effective test of disease to benefit patients. More importantly, it will feed into how healthcare systems implement screening strategies to benefit patient pathways.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores